Resources
8 Results (showing 1 - 8)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 11/11/2021 (updated 4/3/2024)
JBS’s Robert Childs discussed the key concepts of harm reduction and evidence-based harm reduction interventions that grantees can implement to reduce overdose in their rural communities. Staff from Arkansas Behavioral Health Integration Network shared lessons learned from their RCORP-Planning grant in gaining buy-in for harm reduction concepts and planning for harm reduction services in rural Arkansas.
Posted 10/23/2020 (updated 4/3/2024)
These pilot study results suggest comparable safety and effectiveness of unobserved and office induction and point toward utilization of non-inferiority design during future definitive protocol development.
Posted 10/23/2020 (updated 4/3/2024)
This article offers data regarding offering buprenorphine treatment at a public hospital primary care setting using a home, unobserved induction protocol.
Posted 9/1/2021 (updated 4/2/2024)
Posted 2/4/2020 (updated 3/28/2024)
How States are Responding to the Opioid Crisis: An Overview Webinar Presentation and Materials
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 6/8/2022 (updated 3/27/2024)
A collaborative community process to define a town by what it offers the people who live there is the short way to describe the work of placemaking. This digital toolkit from the U.S. Department of Agriculture and the University of Kentucky’s Community and Economic Development Initiative includes examples of rural placemaking projects along with technical assistance providers, funders, and guides to resources.